Malignant Mixed Mullerian tumors of the ovary: The result of Platinum-based combination chemotherapy following the cytoreductive surgery.
- Author:
Jin Young MA
1
;
Yong Man KIM
;
Min Hyung JUNG
;
Sang Min PARK
;
Dae Yeon KIM
;
Jong Hyeok KIM
;
Young Tak KIM
;
Joo Hyun NAM
;
Jung Eun MOK
Author Information
1. Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Korea. ymkim@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Ovary malignant mixed mullerian tumors;
Cytoreductive surgery;
Platinum-based combination chemotherapy
- MeSH:
Chungcheongnam-do;
Drug Therapy;
Drug Therapy, Combination*;
Female;
Gynecology;
Humans;
Korea;
Medical Records;
Obstetrics;
Ovary*;
Retrospective Studies;
Survival Rate
- From:Korean Journal of Gynecologic Oncology
2005;16(1):46-52
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: The purpose of this study was to review the therapeutic results and the clinical outcome of the patients treated with optimal cytoreductive surgery and platinum-based chemotherapy for malignant mixed mullerian tumors (MMMTs) of the ovary. The evaluate the role of such treatments in ovarian MMMTs. METHODS: A retrospective analysis was performed with medical records that nine patients underwent complete surgical staging from February 1993 to January 2004 at Asan Medical Center, Korea. Seven patients received IP (ifosfamide/cisplatin) chemotherapy as a first-line chemotherapy and the other patients received other platinum-based combination chemotherapy. Demographic data, pathologic findings, treatment and survival time were studied. RESULTS: Nine patients diagnosed with MMMTs of the ovary after optimal cytoreductive surgery. The International Federation of Gynecology and Obstetrics stages for the 9 women were none stage I, 1 stage II, 6 stage III, 2 stage IV. The median survival time of all patients was 41 months (1-76 months). The overall survival rate was 55.5% at 1 year and 40% at 2 years. CONCLUSION: Malignant mixed mullerian tumors of the ovary grow very rapidly and are usually in advanced stages when diagnosed. But our results of clinical experience for platinum-based combination chemotherapy after optimal cytoreductive surgery could be a standard treatment for ovarian MMMTs.
